MARLENE MILLAN: Open Payments
NPI 1831846658 · LOMA LINDA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,722 in 172 payments from 14 companies in 2025. Trend: 2023 $1,360 · 2024 $3,212 · 2025 $4,722
Food & beverage: $4,612Education: $109
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $836 |
| E.R. Squibb & Sons, L.L.C. | 27 | $773 |
| Teva Pharmaceuticals USA, Inc. | 22 | $604 |
| Alkermes, Inc. | 20 | $561 |
| Vanda Pharmaceuticals Inc. | 16 | $429 |
| Otsuka America Pharmaceutical, Inc. | 16 | $413 |
| Janssen Pharmaceuticals, Inc | 9 | $267 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $251 |
| Axsome Therapeutics, Inc. | 10 | $238 |
| Novo Nordisk Inc | 1 | $131 |
Products named: VRAYLAR, COBENFY, REXULTI, ARISTADA, UZEDY, FANAPT, CAPLYTA, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
